20 Apr 2021 (Last Updated April 20th, 2021 10:20)
The Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) have reported that the Sputnik V Covid-19 vaccine showed a 97.6% efficacy.
Share Article
Disease incidence among unvaccinated adults was 1.1% from the 35th day after launching mass vaccination in the country. Credit: Alexey Fedenkov / Pixabay.
The Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) have reported that the Sputnik V Covid-19 vaccine showed a 97.6% efficacy.
This was based on the analysis of data on disease infection rate among people receiving both shots of the vaccine.
Winning moment: Russian COVID-19 vaccine Sputnik V found 91.6% efficient in Phase III trial Associated Press
New Delhi: The Gamaleya National Research Centre and the Russian Direct Investment Fund (RDIF) said Tuesday that interim results of the Phase III clinical trials of COVID-19 vaccine ‘Sputnik V’ showed 91.6 per cent efficacy against the pandemic. Medical journal ‘The Lancet’ has published interim results of a Phase III clinical trial of Sputnik V, confirming the vaccine’s high efficacy and safety, they said in a joint statement.
“In the interim efficacy analysis of the randomised, double-blind, placebo-controlled clinical trial, where data on 19,866 volunteers were included in the efficacy analysis (14,964 of whom received the vaccine and 4,902 the placebo) the two-dose treatment of Sputnik V administered 21 days apart demonstrated efficacy of 91.6 per cent against COVID-19,” the statement said.
The News Scroll 02 February 2021
Last Updated at 7:31 pm | Source: PTI
Russian COVID vax found 91.6pc efficient in Phase III trial: RDIF Outlook February 02, 2021 19:31 IST Russian COVID vax found 91.6pc efficient in Phase III trial: RDIF outlookindia.com 1970-01-01T05:30:00+0530
New Delhi, Feb 2 (PTI) The Gamaleya National Research Centre and the Russian Direct Investment Fund (RDIF) on Tuesday said that interim results of a Phase III clinical trial of COVID-19 vaccine Sputnik V showed 91.6 per cent efficacy against the pandemic. Medical journal The Lancet has published interim results of a Phase III clinical trial of Sputnik V, confirming the vaccine s high efficacy and safety, they said in a joint statement.